Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.
Kidney Int
; 102(5): 990-999, 2022 11.
Article
in En
| MEDLINE
| ID: mdl-36272755
Key words
GLP-1 receptor agonist; HbA1c; KDIGO; SGLT2 inhibitor; angiotensin II receptor blocker; angiotensin-converting enzyme inhibitor; chronic kidney disease; dialysis; evidence-based; glycemia; glycemic monitoring; glycemic targets; guideline; hemodialysis; lifestyle; metformin; mineralocorticoid receptor antagonist; models of care; nutrition; reninangiotensin system; self-management; systematic review; team-based care
Full text:
1
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 2
/
Renal Insufficiency, Chronic
Type of study:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Kidney Int
Year:
2022
Type:
Article